Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

Apple and Masimo’s legal battle over the Apple Watch’s Blood Oxygen sensing feature continues this week as both firms meet in ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally ...

Our mission is to improve life, improve patient outcomes; and reduce the cost of care. Masimo SET ® Measure-through Motion and Low Perfusion ™ pulse oximetry, introduced in 1995, has been shown in ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

The global non-invasive respiratory monitoring market is poised for substantial growth, projected to increase from an estimated valuation of USD 8.4 Billion in 2023 to USD 15.0 Billion by 2033, at a ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...